EP3386536A4 - Zusammensetzung aus antikörperkonstrukt-agonisten-konjugaten und verfahren zur verwendung davon - Google Patents
Zusammensetzung aus antikörperkonstrukt-agonisten-konjugaten und verfahren zur verwendung davon Download PDFInfo
- Publication number
- EP3386536A4 EP3386536A4 EP16873755.9A EP16873755A EP3386536A4 EP 3386536 A4 EP3386536 A4 EP 3386536A4 EP 16873755 A EP16873755 A EP 16873755A EP 3386536 A4 EP3386536 A4 EP 3386536A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- methods
- antibody construct
- agonist conjugates
- conjugates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000556 agonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562264260P | 2015-12-07 | 2015-12-07 | |
US15/173,075 US20170158772A1 (en) | 2015-12-07 | 2016-06-03 | Compositions of antibody construct - agonist conjugates and methods of use thereof |
US201662371141P | 2016-08-04 | 2016-08-04 | |
PCT/US2016/065353 WO2017100305A2 (en) | 2015-12-07 | 2016-12-07 | Composition of antibody construct-agonist conjugates and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3386536A2 EP3386536A2 (de) | 2018-10-17 |
EP3386536A4 true EP3386536A4 (de) | 2019-07-31 |
Family
ID=59013332
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16873755.9A Withdrawn EP3386536A4 (de) | 2015-12-07 | 2016-12-07 | Zusammensetzung aus antikörperkonstrukt-agonisten-konjugaten und verfahren zur verwendung davon |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3386536A4 (de) |
CA (1) | CA3007311A1 (de) |
DE (1) | DE212016000029U1 (de) |
WO (1) | WO2017100305A2 (de) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20180688A1 (es) | 2015-08-13 | 2018-04-23 | Merck Sharp & Dohme | Compuestos di-nucleotidos ciclicos como agonistas de sting |
US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
SG11201807660QA (en) | 2016-03-18 | 2018-10-30 | Immune Sensor Llc | Cyclic di-nucleotide compounds and methods of use |
KR20230149857A (ko) | 2016-07-07 | 2023-10-27 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
SI3523287T1 (sl) | 2016-10-04 | 2021-11-30 | Merck Sharp & Dohme Corp. | Benzo(b)tiofenske spojine kot agonisti STING |
JOP20170192A1 (ar) * | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
CA3049842A1 (en) * | 2017-02-02 | 2018-08-09 | Silverback Therapeutics, Inc. | Construct-peptide compositions and methods of use thereof |
AR113224A1 (es) * | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
WO2018208667A1 (en) | 2017-05-12 | 2018-11-15 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
JP2020529421A (ja) | 2017-08-04 | 2020-10-08 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | がんの処置のためのPD−1アンタゴニストおよびベンゾ[b]チオフェンSTINGアゴニストの組み合わせ |
AU2018311966A1 (en) | 2017-08-04 | 2020-02-13 | Merck Sharp & Dohme Llc | Benzo[b]thiophene sting agonists for cancer treatment |
CN107365361B (zh) * | 2017-08-21 | 2020-05-19 | 中国药科大学 | 与pd-l1结合的重复域锚定蛋白及其用途 |
KR102651946B1 (ko) * | 2017-08-31 | 2024-03-26 | 브리스톨-마이어스 스큅 컴퍼니 | 항암제로서의 시클릭 디뉴클레오티드 |
EP3676279B1 (de) * | 2017-08-31 | 2021-12-01 | Bristol-Myers Squibb Company | Cyclische dinukleotide als antikrebsmittel |
WO2019051489A1 (en) * | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE |
WO2019051488A1 (en) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE |
TW201922263A (zh) | 2017-11-10 | 2019-06-16 | 日商武田藥品工業股份有限公司 | 干擾素基因刺激蛋白之調節化合物,及製造和使用方法 |
EP3727401A4 (de) | 2017-12-20 | 2022-04-06 | Merck Sharp & Dohme Corp. | Cyclische di-nukleotid-verbindungen als sting-agonisten |
EP3505188A1 (de) | 2017-12-29 | 2019-07-03 | Invivogen | Procyclische dinukleotidkonjugate zur cytokininduktion |
JP7326319B2 (ja) | 2018-04-03 | 2023-08-15 | メルク・シャープ・アンド・ドーム・エルエルシー | Stingアゴニストとしてのベンゾチオフェン類及び関連する化合物 |
EP3774765A4 (de) | 2018-04-03 | 2021-12-29 | Merck Sharp & Dohme Corp. | Aza-benzothiophenverbindungen als sting-agonisten |
EP3802534B1 (de) | 2018-05-25 | 2022-07-13 | Incyte Corporation | Tricyclische heterocyclische verbindungen als sting-aktivatoren |
WO2020028565A1 (en) | 2018-07-31 | 2020-02-06 | Incyte Corporation | Tricyclic heteraryl compounds as sting activators |
US10875872B2 (en) | 2018-07-31 | 2020-12-29 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
US20220008549A1 (en) | 2018-09-06 | 2022-01-13 | Daiichi Sankyo Company, Limited | Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof |
US11596692B1 (en) | 2018-11-21 | 2023-03-07 | Incyte Corporation | PD-L1/STING conjugates and methods of use |
EP3937984A1 (de) | 2019-03-15 | 2022-01-19 | Bolt Biotherapeutics, Inc. | Gegen her2 gerichtete immunkonjugate |
EP3962493A2 (de) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Verfahren zur modulation der immunreaktivität/konzentration von irf oder sting oder zur behandlung von krebs mit der verabreichung eines sting-modulators und/oder eines purinergischen rezeptormodulators oder eines postzellularen signalisierungsfaktors |
JP2022531899A (ja) | 2019-05-09 | 2022-07-12 | アリゴス セラピューティクス インコーポレイテッド | Stingモジュレータとしての修飾環状ジヌクレオシド化合物 |
MX2021014867A (es) * | 2019-06-03 | 2022-03-25 | Univ Chicago | Metodos y composiciones para el tratamiento del cancer con adyuvantes dirigidos al cancer. |
WO2020245321A1 (en) | 2019-06-04 | 2020-12-10 | Institut Curie | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF |
CN114786729B (zh) | 2019-07-19 | 2023-12-19 | 免疫传感器治疗股份有限公司 | 抗体-sting激动剂缀合物及其在免疫疗法中的用途 |
TW202120500A (zh) | 2019-08-02 | 2021-06-01 | 美商梅爾莎納醫療公司 | 干擾素基因刺激蛋白(sting)激動劑化合物及用途 |
CA3148694A1 (en) * | 2019-09-03 | 2021-03-11 | Romas Kudirka | Aminoquinoline compounds, immunoconjugates, and uses thereof |
WO2021110987A1 (en) | 2019-12-06 | 2021-06-10 | Life & Soft | Methods and apparatuses for diagnosing cancer from cell-free nucleic acids |
CN111233850B (zh) * | 2020-01-21 | 2022-09-23 | 南开大学 | 含苯并噻唑氨基和杂芳基的萘酚衍生物与制备方法和用途 |
EP4106819A1 (de) | 2020-02-21 | 2022-12-28 | Silverback Therapeutics, Inc. | Nectin-4-antikörper-konjugate und verwendungen davon |
IL296124A (en) | 2020-03-06 | 2022-11-01 | Daiichi Sankyo Co Ltd | Conjugation of an antibody with a drug including a novel cyclic dinucleotide derivative |
EP4117790A1 (de) | 2020-03-13 | 2023-01-18 | Hephaistos-Pharma | Entgiftete lipopolysaccharide (lps), natürlich nichttoxisches lps und verwendungen davon |
US20210380695A1 (en) | 2020-05-15 | 2021-12-09 | Immunesensor Therapeutics, Inc. | Sting agonist combination treatments with immune checkpoint inhibitors |
WO2022006327A1 (en) | 2020-07-01 | 2022-01-06 | Silverback Therapeutics, Inc. | Anti-asgr1 antibody conjugates and uses thereof |
EP3943505A1 (de) | 2020-07-22 | 2022-01-26 | Encefa | Cd38-bindende-cd31-peptide und verwendungen davon |
AU2021338014A1 (en) | 2020-09-02 | 2023-03-09 | Daiichi Sankyo Company, Limited | Novel endo-β-N-acetylglucosaminidase |
WO2022097117A1 (en) | 2020-11-09 | 2022-05-12 | Takeda Pharmaceutical Company Ltd. | Antibody drug conjugates |
WO2022117764A1 (en) | 2020-12-02 | 2022-06-09 | Institut Curie | FUNCTIONALIZED SHIGA TOXIN B-SUBUNIT (STxB) PROTEINS AND CONJUGATES THEREOF |
KR20230152073A (ko) | 2021-02-26 | 2023-11-02 | 브레누스 파마 | 비자가 다중 스트레스성 암 세포 및 암의 백신접종 및 치료를 위한 이의 용도 |
JP2024526874A (ja) | 2021-07-23 | 2024-07-19 | イミューンセンサー セラピューティクス、インコーポレイテッド | サイトカインとのstingアゴニスト併用療法 |
CN118369344A (zh) | 2021-09-16 | 2024-07-19 | 阿博莱斯制药公司 | 抗人cd45rc结合结构域及其用途 |
TW202342105A (zh) * | 2021-12-17 | 2023-11-01 | 大陸商北京加科思新藥研發有限公司 | 包含可用作sting激動劑的化合物的化合物-連接基構建體及其用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015103987A1 (en) * | 2014-01-10 | 2015-07-16 | Shanghai Birdie Biotech, Inc. | Compounds and compositions for treating her2 positive tumors |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1456092A (en) * | 1991-02-21 | 1992-09-15 | Gilead Sciences, Inc. | Aptamers specific for thrombin and methods of use |
WO1995026325A2 (en) | 1994-03-25 | 1995-10-05 | Isotechnika Inc. | Enhancement of the efficacy of drugs by deuteration |
US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
US8946387B2 (en) * | 2002-08-14 | 2015-02-03 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
KR20200075023A (ko) * | 2012-05-04 | 2020-06-25 | 화이자 인코포레이티드 | 전립선 관련된 항원 및 백신 기재 면역치료 요법 |
-
2016
- 2016-12-07 CA CA3007311A patent/CA3007311A1/en not_active Abandoned
- 2016-12-07 WO PCT/US2016/065353 patent/WO2017100305A2/en active Application Filing
- 2016-12-07 EP EP16873755.9A patent/EP3386536A4/de not_active Withdrawn
- 2016-12-07 DE DE212016000029.2U patent/DE212016000029U1/de not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015103987A1 (en) * | 2014-01-10 | 2015-07-16 | Shanghai Birdie Biotech, Inc. | Compounds and compositions for treating her2 positive tumors |
Non-Patent Citations (2)
Title |
---|
ADAM J. R. GADD ET AL: "Targeted Activation of Toll-Like Receptors: Conjugation of a Toll-Like Receptor 7 Agonist to a Monoclonal Antibody Maintains Antigen Binding and Specificity", BIOCONJUGATE CHEMISTRY, vol. 26, no. 8, 16 July 2015 (2015-07-16), US, pages 1743 - 1752, XP055455345, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.5b00302 * |
SINGH S.K., LUISI D.L. & PAK R.H.: "Antibody-Drug Conjugates: Design, Formulationand Physicochemical Stability", PHARM. RES., vol. 32, 19 May 2015 (2015-05-19), pages 3541 - 3571, XP002792278 * |
Also Published As
Publication number | Publication date |
---|---|
DE212016000029U1 (de) | 2017-07-30 |
WO2017100305A8 (en) | 2017-09-08 |
WO2017100305A3 (en) | 2017-07-20 |
EP3386536A2 (de) | 2018-10-17 |
CA3007311A1 (en) | 2017-06-15 |
WO2017100305A2 (en) | 2017-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3386536A4 (de) | Zusammensetzung aus antikörperkonstrukt-agonisten-konjugaten und verfahren zur verwendung davon | |
EP3383430A4 (de) | Antikörper und verfahren zur verwendung davon | |
HK1257056A1 (zh) | 抗dll3抗體藥物綴合物以及使用方法 | |
EP3504243A4 (de) | Anti-tim-3-antikörper und verwendung davon | |
EP3515478A4 (de) | Antikörper für siglec-15 und verfahren zur verwendung davon | |
EP3280441A4 (de) | Anti-sortilin-antikörper und verfahren zur verwendung davon | |
EP3383914A4 (de) | Anti-ox40-antikörper und verfahren zur verwendung davon | |
EP3316909A4 (de) | Anti-ntb-a-antikörper sowie zugehörige zusammensetzungen und verfahren | |
EP3397276A4 (de) | Antikörper und konjugate davon | |
EP3177322A4 (de) | Anti-trem2-antikörper und verfahren zur verwendung davon | |
EP3151830A4 (de) | Anti-her2-antikörper-maytansin-konjugate und verfahren zur verwendung davon | |
EP3363816A4 (de) | Anti-ox40-antikörper und verwendungen davon | |
EP3383917A4 (de) | Neuartige anti-claudin-antikörper und verfahren zur verwendung | |
EP3283517A4 (de) | Anti-pacap-antikörper und verwendungen davon | |
EP3134121A4 (de) | Neuartige anti-rnf43-antikörper und verfahren zur verwendung | |
EP3341021A4 (de) | Anti-alk-antikörper und verfahren zur verwendung davon | |
EP3270965A4 (de) | Cd48-antikörper und konjugate davon | |
EP3394098A4 (de) | Anti-myostatin-antikörper und verfahren zur verwendung | |
EP3248005A4 (de) | Neuartige glycankonjugate und verfahren zur verwendung davon | |
EP3386986A4 (de) | Gold-porphyrin-peg-konjugate und verfahren zur verwendung | |
EP3294341A4 (de) | Zusammensetzungen und verfahren zur herstellung von antikörperkonjugaten | |
EP3189079A4 (de) | Neuartige anti-mfi2-antikörper und verfahren zur verwendung | |
EP3559042A4 (de) | Anti-lilrb3-antikörper und verfahren zur verwendung davon | |
EP3283493A4 (de) | Texaphyrin-phospholipid-konjugate und verfahren zur herstellung davon | |
EP3285805A4 (de) | Therapeutische antikörper und verwendungen davon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20180706 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20190701 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/32 20060101ALI20190624BHEP Ipc: A61K 39/395 20060101ALI20190624BHEP Ipc: A61K 39/39 20060101ALI20190624BHEP Ipc: C07K 16/28 20060101ALI20190624BHEP Ipc: A61K 47/68 20170101ALI20190624BHEP Ipc: A61K 39/00 20060101AFI20190624BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1261040 Country of ref document: HK |
|
17Q | First examination report despatched |
Effective date: 20200213 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20200624 |